CA3174699A1 - Ginsenoside compositions - Google Patents
Ginsenoside compositionsInfo
- Publication number
- CA3174699A1 CA3174699A1 CA3174699A CA3174699A CA3174699A1 CA 3174699 A1 CA3174699 A1 CA 3174699A1 CA 3174699 A CA3174699 A CA 3174699A CA 3174699 A CA3174699 A CA 3174699A CA 3174699 A1 CA3174699 A1 CA 3174699A1
- Authority
- CA
- Canada
- Prior art keywords
- ginsenosides
- composition
- increasing
- gut microbiota
- scfas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2004121.6A GB202004121D0 (en) | 2020-03-20 | 2020-03-20 | Improved compositions |
| GB2004121.6 | 2020-03-20 | ||
| GB2005288.2 | 2020-04-09 | ||
| GBGB2005288.2A GB202005288D0 (en) | 2020-04-09 | 2020-04-09 | Improved compositions |
| PCT/EP2021/056803 WO2021185897A1 (en) | 2020-03-20 | 2021-03-17 | Ginsenoside compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3174699A1 true CA3174699A1 (en) | 2021-09-23 |
Family
ID=75108332
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3174699A Pending CA3174699A1 (en) | 2020-03-20 | 2021-03-17 | Ginsenoside compositions |
| CA3174698A Pending CA3174698A1 (en) | 2020-03-20 | 2021-03-17 | Ginsenoside compositions |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3174698A Pending CA3174698A1 (en) | 2020-03-20 | 2021-03-17 | Ginsenoside compositions |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20230124503A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4121061A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7808042B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN115315264A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2021238639B2 (cg-RX-API-DMAC7.html) |
| BR (2) | BR112022015826A2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3174699A1 (cg-RX-API-DMAC7.html) |
| WO (2) | WO2021185897A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230124503A1 (en) * | 2020-03-20 | 2023-04-20 | Givaudan Sa | Ginsenoside compositions |
| JP2023161983A (ja) * | 2022-04-26 | 2023-11-08 | 石川県公立大学法人 | サポニンを含む酪酸産生菌増殖能向上組成物、腸内常在菌増殖能向上組成物、乳酸菌増殖能向上組成物及びビフィズス菌増殖能向上組成物 |
| CN117224553B (zh) * | 2023-11-02 | 2025-08-12 | 浙江大学 | 人参皂苷Rg3在制备治疗或预防肠道病毒感染的药物中的应用 |
| CN117752706B (zh) * | 2023-12-20 | 2025-10-14 | 浙江天皇药业有限公司 | 西洋参炮制品在制备治疗甲状腺功能减退症药物中的应用 |
| WO2025261873A1 (en) | 2024-06-20 | 2025-12-26 | Givaudan Sa | Improvements in or relating to compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040202731A1 (en) * | 2003-04-08 | 2004-10-14 | Gow Robert T. | Rosmarinic acid composition |
| US20100278944A1 (en) * | 2009-05-04 | 2010-11-04 | Naturex, S.A. | Application of american ginseng to enhance neurocognitive function |
| US9956241B2 (en) * | 2009-05-04 | 2018-05-01 | Naturex, S.A. | Application of American Ginseng to enhance neurocognitive function |
| KR102200012B1 (ko) * | 2013-04-02 | 2021-01-08 | (주)아모레퍼시픽 | 인삼열매 추출물을 포함하는 뇌 활성화 조성물 |
| US10456436B2 (en) * | 2013-11-04 | 2019-10-29 | Wen Luan Wendy Hsiao | Use of herbal saponins to regulate gut microflora |
| BR112020000963A2 (pt) | 2017-07-18 | 2020-07-14 | Senescence Life Sciences Pte. Ltd. | composições e métodos para o tratamento e prevenção de declínio cognitivo e conservação da função neuronal |
| CN110613802A (zh) * | 2018-06-20 | 2019-12-27 | 珠海岐微生物科技有限公司 | 白茅根大黄炭三七组合物及其在调节肠道微生物中的用途 |
| CN109432304A (zh) * | 2018-12-03 | 2019-03-08 | 杭州胡庆余堂药业有限公司 | 一种含铁皮石斛组合物在药物制备中的应用 |
| US20230124503A1 (en) | 2020-03-20 | 2023-04-20 | Givaudan Sa | Ginsenoside compositions |
-
2021
- 2021-03-17 US US17/905,849 patent/US20230124503A1/en active Pending
- 2021-03-17 WO PCT/EP2021/056803 patent/WO2021185897A1/en not_active Ceased
- 2021-03-17 EP EP21712999.8A patent/EP4121061A1/en active Pending
- 2021-03-17 BR BR112022015826A patent/BR112022015826A2/pt unknown
- 2021-03-17 CA CA3174699A patent/CA3174699A1/en active Pending
- 2021-03-17 AU AU2021238639A patent/AU2021238639B2/en active Active
- 2021-03-17 BR BR112022016241A patent/BR112022016241A2/pt unknown
- 2021-03-17 CN CN202180022225.5A patent/CN115315264A/zh active Pending
- 2021-03-17 WO PCT/EP2021/056788 patent/WO2021185890A1/en not_active Ceased
- 2021-03-17 CA CA3174698A patent/CA3174698A1/en active Pending
- 2021-03-17 CN CN202180022249.0A patent/CN115315266A/zh active Pending
- 2021-03-17 US US17/905,868 patent/US20230129389A1/en active Pending
- 2021-03-17 EP EP21713906.2A patent/EP4121076A1/en active Pending
- 2021-03-17 JP JP2022555990A patent/JP7808042B2/ja active Active
- 2021-03-17 AU AU2021238643A patent/AU2021238643A1/en active Pending
- 2021-03-17 JP JP2022556000A patent/JP7850670B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021238639B2 (en) | 2026-06-25 |
| EP4121061A1 (en) | 2023-01-25 |
| WO2021185897A1 (en) | 2021-09-23 |
| US20230129389A1 (en) | 2023-04-27 |
| AU2021238643A1 (en) | 2022-10-20 |
| WO2021185890A1 (en) | 2021-09-23 |
| US20230124503A1 (en) | 2023-04-20 |
| BR112022015826A2 (pt) | 2022-10-04 |
| CN115315264A (zh) | 2022-11-08 |
| CA3174698A1 (en) | 2021-09-23 |
| EP4121076A1 (en) | 2023-01-25 |
| BR112022016241A2 (pt) | 2022-10-11 |
| JP7850670B2 (ja) | 2026-04-23 |
| JP2023518064A (ja) | 2023-04-27 |
| JP2023519189A (ja) | 2023-05-10 |
| JP7808042B2 (ja) | 2026-01-28 |
| CN115315266A (zh) | 2022-11-08 |
| AU2021238639A1 (en) | 2022-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230124503A1 (en) | Ginsenoside compositions | |
| Tian et al. | Digestive characteristics of Hericium erinaceus polysaccharides and their positive effects on fecal microbiota of male and female volunteers during in vitro fermentation | |
| Liu et al. | Microbiome and metabolome integrally reveal the anti-depression effects of Cistanche deserticola polysaccharides from the perspective of gut homeostasis | |
| Chen et al. | Dietary saponins from four popular herbal tea exert prebiotic-like effects on gut microbiota in C57BL/6 mice | |
| CA3161418C (en) | Multi-strain probiotic composition and its use | |
| Martirosyan et al. | The bioactive compounds of probiotic foods/supplements and their application in managing mental disorders | |
| Campaniello et al. | A narrative review on the use of probiotics in several diseases. Evidence and perspectives | |
| WO2022127934A1 (zh) | 人参皂苷在改善肠道菌群结构和/或肠屏障功能的应用 | |
| JPWO2008155999A1 (ja) | Gaba作動性ニューロン賦活剤 | |
| US20210121505A1 (en) | Compositions and methods for treating inflammatory bowel diseases | |
| JP2022518261A (ja) | プレバイオティクス剤として使用するための酵母製品およびそれを含む組成物 | |
| Florina et al. | The interdependence between diet, microbiome, and human body health-A systemic review | |
| JP7514926B2 (ja) | 個別化腸内細菌叢の多様性を整える機能を有する組成物及び使用 | |
| JP2011178700A (ja) | 錠剤および錠剤製造方法 | |
| Lan et al. | Protective mechanisms of Hovenia dulcis Thunb extracts on acute alcoholism and liver injury | |
| WO2020049560A1 (en) | Methods for supporting weight loss and weight loss maintenance by administration of aquatic plants and/or autologous microbiome samples | |
| Yang et al. | The regulatory effects of Lonicera japonica flos on fecal microbiota from humans with type 2 diabetes in a SHIME model | |
| Yang et al. | The short-term and long-term effects of Dendrobium officinale leaves polysaccharides on the gut microbiota differ | |
| Li et al. | Hemp seed oil ameliorates CFA-induced rheumatoid arthritis in rats by improving metabolic abnormalities and gut microflora | |
| WO2023000408A1 (zh) | 包含β-烟酰胺单核苷酸和刺梨提取物的组合物及其应用 | |
| TWI810645B (zh) | 乳桿菌組合物及其改善抗生素造成之焦慮症的用途 | |
| JP7500897B2 (ja) | 腸内菌叢改善用組成物 | |
| Chi | Study on biofate and antidepressive mechanism of fructooligosaccharides from Morinda officinalis | |
| EP3370751B1 (en) | Lentil extract with cholesterol lowering and prebiotic activity | |
| JP2024018368A (ja) | 腸内細菌叢改善用組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250307 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250307 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250307 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250311 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250311 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250311 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250313 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250324 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250324 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250324 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250512 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260309 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260309 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260311 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260616 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260625 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260625 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260625 |